SETD2

Across TCGA pan-cancer cohorts, SETD2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SETD2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SETD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SETD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, ESCA, and UCEC are the cancer types where SETD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
UCEC	DFS	Median	II,III,IV	0.901	0.297	.004	26	view →
LUAD	DFS	Median	All	0.206	0.665	<.001	13	view →
PCPG	OS	Median	All	0.010	0.946	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.016	6	view →
LGG	DFS	Median	All	0.156	0.753	<.001	3	view →
KIRP	OS	Median	All	0.746	0.906	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SETD2–THYM (OS)

Open the THYM breakdown →